Our CGO, Eric Huckins, VP of Specialty Pharmacy Supply Chain, Michael DePaz and Director of Industry Relations and Contracting, Jamie Palzkill, sat down with the Becker’s Healthcare Podcast to discuss how innovative partnerships & new pharmacy models can help health systems address rising drug costs while improving patient access and affordability.
This year’s drug trend report highlights key trends that shaped 2025 and how those will extend into the coming years, including the continued growth and complexity of specialty medications. Take a few minutes to explore the full report and learn more about the trends impacting patients, providers and–most importantly–specialty care.
This report demonstrated that integration of pharmacy liaisons and pharmacists into the appeals process represents a cost-effective, sustainable solution to the administrative challenges faced by prescribers.
Lumicera Health Services today announced the launch of Clarventa, a new company created to address one of the most persistent drivers of rising prescription drug costs: the complex and opaque pharmaceutical supply chain.
Lumicera Health Services is proud to announce that Eric Huckins has been promoted to Chief Growth Officer, a role in which he will guide the next stage of Lumicera’s expansion, partnerships and specialty pharmacy innovation.
Lumicera Earns URAC Rare Disease Pharmacy Center of Excellence Certification, Reinforcing Commitment to Specialized Patient Care.
Lumicera announces the promotion of Ben Heiser, PharmD, to Senior Vice President and Chief Executive Officer (CEO) during a period of historic growth!
Eric Huckins, our Vice President of Business Development, sat down with the Becker’s Healthcare Podcast Network during their CPO Summit to share his insights on specialty pharmacy for health systems.
At Lumicera, clinical excellence isn’t just a goal, it’s the heart of everything we do. Our dedicated pharmacy team goes above and beyond to provide personalized, patient-focused care each and every day!
This report analyzed the patient acceptance rate and reported outcomes when a pharmacist provided interventions for patients on oral targeted breast cancer therapies in a mail order integrated health system specialty pharmacy.
